On-demand webinar

On-demand webinar: Handling your antibody drug conjugate

Posted: 14 March 2022 | | No comments yet

ADCs have huge potential in treating challenging diseases. It is essential that all necessary steps are in place to ensure their safe handling.

Lonza - 14 March 2022

ADCs are biological drugs that comprise a highly toxic payload joined to an antibody with a linker moiety. They are commonly treated as highly potent because of the toxicity of the payload, which is typically active at a very low dose. As a result, there are strict requirements for containment during their manufacture. For a CDMO, specialised in-house occupational toxicology and industrial hygiene expertise is essential to ensure the safe handling of the ADCs they are developing.